AAD 2019

Read the full Report (pdf)
American Academy of Dermatology
1–5 March 2019 Washington DC, USA
Featured articles

Interview with AAD president Prof. George J. Hruza
CONTENTS
Online First
Late-Breakers
Secukinumab maintains improvements in psoriasis through 5 years of treatment
Bermekimab – a future treatment for atopic dermatitis?
JAK1/2 inhibitor effective in alopecia areata
Novel anti-IgE drug enables durable urticaria control
Dual IL-17A and IL-17F blocker leads to unprecedented response rates in psoriasis
Thicker AK lesions benefit from laser pretreatment with high channel density
New standardised cantharidin product against molluscum contagiosum efficacious in two phase 3 trials

Bruton’s tyrosine kinase inhibitor highly effective in pemphigus vulgaris
Serlopitant reduces pruritus associated with psoriasis
Atopic Dermatitis: Many New Therapies in the Pipeline

New and emerging atopic dermatitis therapies
Food triggers eczema – an imperturbable belief of patients
Psoriasis and Biologics: The Beat Goes On
Psoriasis and Biologics: The Beat Goes On
JAK Inhibitors: A New Frontier in Dermatology
JAK inhibitors: a new therapeutic tool for dermatologists
JAK inhibitors: a pathogenesis-directed therapy for alopecia areata
Can JAK inhibitors close the current therapeutic gap in AD?
Hair Loss: No Reason for Therapeutic Nihilism

Hair Loss: No Reason for Therapeutic Nihilism
Vitiligo: The Beginning of a New Era

Vitiligo in children
Surgical treatment for selected vitiligo cases
JAK-inhibitors: an emerging treatment option for vitiligo
What's New and Hot in Acne

Oral antibiotics for acne treatment
Should we use more hormonal therapy?
Pearls of the Posters
Plaque psoriasis – Efficacy of guselkumab
Pemphigus patients prone to osteoporosis
